Blood-based Biomarkers Used to Predict Disease Activity in Crohnʼs Disease and Ulcerative Colitis

Burakoff, Robert; Pabby, Vikas; Onyewadume, Louisa; Odze, Robert D.; Adackapara, Cheryl; Wang, Wei; Friedman, Sonia; Hamilton, M. W.; Korzenik, Joshua R.; Levine, Jonathan; Makrauer, Frederick L.; Cheng, Changming; Smith, H; Liew, Choong‐Chin; Chao, Samuel T.

doi:10.1097/mib.0000000000000340

Cited by 28 publications

(26 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although CRP is used as a biomarker for disease activity in UC, it does not always reflect the mucosal inflammation. 31,32 In the present study, although most patients presented with normal CRP levels, the activation status of MAIT cells in the peripheral blood, such as the expression levels of CD69, correlated with clinical disease activity and endoscopic scores. Our findings suggest that MAIT cells may serve as a biomarker for mucosal inflammation in UC.…”

Section: Discussionmentioning

confidence: 43%

“…Recent therapeutic options for UC involve evaluation of mucosal inflammatory conditions in order to choose an effective treatment strategy. Although CRP is used as a biomarker for disease activity in UC, it does not always reflect the mucosal inflammation . In the present study, although most patients presented with normal CRP levels, the activation status of MAIT cells in the peripheral blood, such as the expression levels of CD69, correlated with clinical disease activity and endoscopic scores.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

MAIT cells are activated and accumulated in the inflamed mucosa of ulcerative colitis

Haga

Chiba

Shibuya

et al. 2016

J of Gastro and Hepatol

116

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 43%

Section: Discussionmentioning

confidence: 99%

MAIT cells are activated and accumulated in the inflamed mucosa of ulcerative colitis

Haga

Chiba

Shibuya

et al. 2016

J of Gastro and Hepatol

116

View full text Add to dashboard Cite

show abstract

“…56 More recently, the Affymetrix GeneChip technology was utilized to generate genome-wide expression profiles to predict disease activity in patients with UC and CD. 57 In this study, whole blood gene panels determined the activity of disease with high sensitivity and specificity, while reliably distinguishing between UC and CD. 57 While these initial results are promising, the majority of studies evaluating the utility of whole blood gene expression analysis have been performed in small populations, and thus larger studies remain necessary for further evaluation of this modality.…”

Section: New Approaches To Biomarkersmentioning

confidence: 93%

New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes

Barnes

Burakoff²

2016

Inflammatory Bowel Diseases

Self Cite

View full text Add to dashboard Cite

Despite advances in our understanding of the pathophysiology underlying Inflammatory Bowel Disease (IBD), there remains a significant need for biomarkers that can differentiate between Crohn's Disease (CD) and Ulcerative Colitis (UC) with high sensitivity and specificity, in a cost-efficient manner. As the focus on personalized approaches to the delivery of medical treatment increases, new biomarkers are being developed to predict an individual's response to therapy as well as their overall disease course. In this review, we will outline many of the existing and recently developed biomarkers, detailing their role in the assessment of patients with IBD. We will identify opportunities for improvement in our biomarkers, including better differentiation between the subtypes of IBD. We will also discuss new targets and strategies in biomarker development, including combining modalities to create biomarker signatures to improve the ability to predict disease courses and response to therapy among individual patients.

show abstract

“…However, besides being associated with significant procedural risks, colonoscopy is an invasive and expensive procedure. Therefore, non-invasive assessment is considered as the ideal mainstay of routine disease monitoring and many efforts have been made to identify laboratory biomarkers that can be used as an objective measure of disease activity and can help to diminish the need for colonoscopy 5 6…”

Section: Introductionmentioning

confidence: 99%

Serum St2 in Inflammatory Bowel Disease: A Potential Biomarker for Disease Activity

Boğa

Alkım

Koksal

et al. 2016

Journal of Investigative Medicine

View full text Add to dashboard Cite

ST2, a specific ligand of interleukin 33, was described as a biomarker protein of inflammatory processes and overexpression of ST2 in ulcerative colitis (UC) was shown previously. We aimed to investigate the potential relationship of serum ST2 levels with the clinical, endoscopic and histopathological activity scores in UC and Crohn's disease (CD). Serum ST2 levels were determined in 143 patients with inflammatory bowel disease (IBD) (83 UC and 60 CD), in 50 healthy controls (HC), and in 32 patients with irritable bowel syndrome (IBS). Serum ST2 levels were elevated in IBD (56.8 (41.9-87.2) pg/mL) compared to HC and IBS (30.7 (20.2-54.3), p<0.001 and 39.9 (25.9-68.7) pg/mL, p=0.002, respectively). No significant difference was found between UC (54.2 (41.3-93.0) pg/mL) and CD (63.8 (42.7-88.4) pg/mL) and between IBS and HC. Serum ST2 levels were significantly increased in active UC compared to inactive UC (72.5 (44.1-99.5) vs 40.0 (34.7-51.6) pg/mL, p<0.001) and in active CD in comparison with inactive CD (63.8 (42.7-88.4) vs 48.4 (29.6-56.9) pg/mL, p=0.036). Patients with CD showing fistulizing behavior had significantly higher ST2 levels compared to patients with inflammatory and stricturing CD (p<0.001). Clinical activity scores of patients with UC and CD were correlated with serum ST2 levels (r=0.692, p<0.001 and r=0.242, p=0.043, respectively). Serum ST2 levels showed stepwise increases with the increasing histopathological scores of patients with UC and CD (p<0.001 for both). The present study highlights significant associations between ST2 and IBD presence and activity and demonstrates elevated serum ST2 levels in patients with active CD as a novel finding.

show abstract

Blood-based Biomarkers Used to Predict Disease Activity in Crohnʼs Disease and Ulcerative Colitis

Abstract: The specific whole blood gene panels reliably distinguished CD and UC and determined the activity of disease, with high sensitivity and specificity in our cohorts of patients. This simple serological test has the potential to become a biomarker to determine the activity of disease.

Cited by 28 publications

References 32 publications

MAIT cells are activated and accumulated in the inflamed mucosa of ulcerative colitis

MAIT cells are activated and accumulated in the inflamed mucosa of ulcerative colitis

New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes

Serum St2 in Inflammatory Bowel Disease: A Potential Biomarker for Disease Activity

Contact Info

Product

Resources

About